1. Home
  2. IIIV vs PEPG Comparison

IIIV vs PEPG Comparison

Compare IIIV & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo i3 Verticals Inc.

IIIV

i3 Verticals Inc.

N/A

Current Price

$18.72

Market Cap

304.5M

Sector

Technology

ML Signal

N/A

Logo PepGen Inc.

PEPG

PepGen Inc.

N/A

Current Price

$4.39

Market Cap

364.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IIIV
PEPG
Founded
2012
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
304.5M
364.3M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
IIIV
PEPG
Price
$18.72
$4.39
Analyst Decision
Buy
Strong Buy
Analyst Count
4
8
Target Price
★ $25.50
$12.75
AVG Volume (30 Days)
259.3K
★ 5.2M
Earning Date
11-17-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 25.61
EPS
★ 0.24
N/A
Revenue
N/A
N/A
Revenue This Year
$2.13
N/A
Revenue Next Year
$4.90
N/A
P/E Ratio
$77.69
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.63
$1.31
52 Week High
$29.69
$7.80

Technical Indicators

Market Signals
Indicator
IIIV
PEPG
Relative Strength Index (RSI) 61.07 65.87
Support Level $18.47 $1.50
Resistance Level $23.29 $5.37
Average True Range (ATR) 0.65 0.44
MACD 0.03 0.28
Stochastic Oscillator 72.25 50.35

Price Performance

Historical Comparison
IIIV
PEPG

About IIIV i3 Verticals Inc.

i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.

Share on Social Networks: